New drug for treatment of schizophrenia launched in Kenya
By Our Reporter
The Pharmacy and Poisons Board (PPB) has approved the use of Paliperidone Palmitate, manufactured by Janssen, pharmaceutical companies of Johnson & Johnson, for the maintenance treatment of schizophrenia in adults whose disease has already been stabilized on treatment with paliperidone or risperidone.
Paliperidone Palmitate is a second generation long acting injectable antipsychotic which will be administered monthly as a maintenance treatment of patients with schizophrenia. The new drug works as a receptor antagonist of dopamine and serotonin, leading to the stabilization of these two chemicals in the brain.
Janssen Kenya Key account manager/product specialist for Neuro science Dedan Kihara, Lisbon Psychiatrist Hospital centre consultant Dr. Soffia Brissos and Dr. Eric Muchangi Country Medical Affairs Manager Jansen during the launch of Paliperidone Palmitate for the treatment of schizophrenia
The approval is expected to help boost ongoing efforts aimed at addressing the burden of mental illness and access to quality mental health care in Kenya.
The prescription only drug is distributed locally by Johnson & Johnson Middle East FZ LLC, locally known as Janssen Kenya, as part of the global pharmaceutical company´s commitment to enhance access to essential medicines.
Dr Frank Njenga confers with Janssen Country Manager Mr. Marseile Onyango during the launch of Paliperidone Palmitate for the treatment of schizophrenia.
When confirming the recent approval, Janssen Kenya Country Manager Mr. Marseille Onyango noted that burden of schizophrenia and related illnesses was on the rise and the introduction of Paliperidone Palmitate in the market would proliferate access to more treatment options for patients with schizophrenia.
Mr. Marseille Onyango said the pharmaceutical company will continue to support national efforts to de-stigmatize mental health by supporting awareness and capacity building initiatives.
“As a company committed to bringing innovative medicines to patients, we want to play our part and join forces in the national mental health policy rollout agenda as we aspire for better health outcomes for all,” said Onyango.
On his part, Mr. Bassem Haider, Janssen Country Director for Sub Saharan Africa & Syria, emphasized the company’s strong heritage in neuroscience. “We are a proud pioneer in the field. It is our mission to reduce the burden, disability and devastation caused by mental health disorders and transform individual lives.” said Bassem.
Mr. Haider expressed optimism that the new treatment will provide much needed relief for patients with Schizophrenia and their families.
Leave a Reply